Evidence map›Paper›PMID 38171874›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies.

Masao Hagihara, Hiroyoshi Hayashi, Shiori Nakashima, Yui Imai, Hirofumi Nakano, Tomoyuki Uchida, Morihiro Inoue, Yuko Sakai-Tagawa, Mutsumi Ito, Seiya Yamayoshi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masao HagiharaDepartment of Hematology, Eiju General Hospital, Japan.
Hiroyoshi HayashiDepartment of Hematology, Eiju General Hospital, Japan.
Shiori NakashimaDepartment of Hematology, Eiju General Hospital, Japan.
Yui ImaiDepartment of Hematology, Eiju General Hospital, Japan.
Hirofumi NakanoDepartment of Hematology, Eiju General Hospital, Japan.
Tomoyuki UchidaDepartment of Hematology, Eiju General Hospital, Japan.
Morihiro InoueDepartment of Hematology, Eiju General Hospital, Japan.
Yuko Sakai-TagawaDivision of Virology, Institute of Medical Science, The University of Tokyo, Japan.
Mutsumi ItoDivision of Virology, Institute of Medical Science, The University of Tokyo, Japan.
Seiya YamayoshiDivision of Virology, Institute of Medical Science, The University of Tokyo, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Institute of Medical Science, The University of Tokyo, Japan.
Yutaka SuzukiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Japan.
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, The University of Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported in immunocompromised patients, as they poorly develop antibodies against SARS-CoV-2. We conducted a clinical trial to determine the efficacy of Imdevimab/Casirivimab (Imde/Casiri), an anti-viral monoclonal antibody (mAb), for prolonged infection at our institution. Methods Nine patients with hematological malignancies (six with malignant lymphoma and three with multiple myeloma) in our institution presented with coronavirus disease 2019 caused by SARS-CoV-2 omicron variants (one, five, and one with BA.2, BA.5, and BF.7, respectively; two undetermined). Although not all nine patients developed severe disease, viral mRNA was detected in all patients after treatment with remdesivir or molnupiravir. Imde/casiri was infused 11-49 days after the disease onset. Results Within seven days of infusion, viral RNA was undetectable in five of the nine cases. Because all seven viruses isolated from patients whose viral RNA became undetectable showed low or no sensitivity to this monoclonal antibody cocktail, the disappearance of viral RNA in these cases may not be attributable to the antibody cocktail. Conclusion It may be worth considering the use of monoclonal antibodies that show some activity against these virus variants to treat persistent SARS-CoV-2 infection in immunocompromised patients.

Indexed as

Antibodies, Monoclonal, HumanizedHematologic NeoplasmsSARS-CoV-2AdultAgedAged, 80 and overAntibodies, NeutralizingAntiviral AgentsCOVID-19COVID-19 Drug TreatmentDrug CombinationsFemaleHumansImmunocompromised HostMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral Agentscasirivimab and imdevimab drug combinationDrug CombinationsRNA, ViralCOVID-19hematological malignanciesImdevimab/CasirivimabmRNApersistent infection

Identifiers

PMID38171874
PMCPMC11414357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.